Articles From: Infinera to Host Light on a Chip: The Future of Photonic Integration Webinar on December 10, 2014 to Informatica Joins Bluewolf's Global Analytics Practice to Power Business Intelligence


2014/11/24
http://media.marketwire.com/attachments/201104/60146_infineralogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1160846&ProfileId=051205&sourceType=1 SUNNYVALE, CA --
Sign-up for Infinera to Host Light on a Chip: The Future of Photonic Integration Webinar on December 10, 2014 investment picks
2014/10/18
By Dan Neil In the ivied precincts of Larchmont and Old Greenwich, there are driveways that must be served.
Sign-up for Infiniti crossover is a beast of suburban burden investment picks
- Infinity to Receive $275 Million Upfront Payment and $530 Million in Potential Milestones - - Companies to Jointly Develop and Commercialize Duvelisib in U.S., with Equal Profit Share; Infinity to Receive Royalties on Sales Outside the U.S. - - Infinity to Host Conference Call Today at 8:30 A.M. ET/7:30 A.M. CT - CAMBRIDGE, Mass.
Sign-up for Infinity And AbbVie Announce Global Strategic Collaboration To Develop And Commercialize Duvelisib (IPI-145) In Oncology investment picks
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and AbbVie Inc. (NYSE: ABBV) today announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity’s oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer.
Sign-up for Infinity and AbbVie Announce Global Strategic Collaboration to Develop and Commercialize Duvelisib (IPI-145) In Oncology investment picks
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that new data for duvelisib (IPI-145), an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, will be presented at the American Society of Hematology (ASH) 2014 Annual Meeting, which is being held December 6-9 in San Francisco, CA.
Sign-up for Infinity Announces Clinical and Preclincal Data for Duvelisib to Be Presented at ASH 2014 Annual Meeting investment picks
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Thursday, November 6, 2014, at 4:30 p.m. ET.
Sign-up for Infinity Announces the Date of Its Third Quarter 2014 Financial Results Conference Call and Webcast investment picks
Sessions designed to help Spanish-speaking individuals maneuver through the DMV and familiarize them with State vehicle insurance requirements LOS ANGELES , Nov.
Sign-up for Infinity Auto Insurance Hosts AB 60 Informational Workshops investment picks
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it has entered into a master clinical supply agreement with Roche under which Roche will supply Gazyva TM (obinutuzumab) to Infinity for use in planned clinical studies to evaluate the combination of Gazyva and duvelisib (IPI-145), Infinity’s oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with hematologic malignancies, or blood cancers.
Sign-up for Infinity Enters into Master Clinical Supply Agreement and Material Transfer Agreement with Roche investment picks
Shares of Infinity Pharmaceuticals (INFI) soared 46% in premarket trade Wednesday, after the company said it would receive an upfront payment of $275 million from AbbVie (ABBV) as part of a new collaboration to develop and commercialize Infinity's duvelisib, a treatment for blood cancers.
Sign-up for Infinity Pharmaceuticals shares soar after AbbVie collaboration investment picks
BIRMINGHAM, Ala.
Sign-up for Infinity Property And Casualty Corporation Declares Quarterly Dividend investment picks
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today reported its third quarter 2014 financial results and updated its 2014 financial guidance based on the commencement of its global strategic collaboration with AbbVie Inc. to develop and commercialize duvelisib (IPI-145), an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in oncology.
Sign-up for Infinity Reports Third Quarter 2014 Financial Results and Provides Company Update investment picks
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced encouraging topline data from its Phase 2a exploratory study of duvelisib (IPI-145), its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with mild, allergic asthma.
Sign-up for Infinity Reports Topline Data from Phase 2a Exploratory Study of Duvelisib in Patients with Mild, Allergic Asthma investment picks
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be participating in the following four upcoming conferences in November: A live webcast of Infinity's presentations at the Credit Suisse, Stifel and Goldman conferences will be accessible on the “investors/media” section of the company's website, www.infi.com , and will be available for 30 days following each event.
Sign-up for Infinity to Participate in Four Conferences in November investment picks
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be participating in the following upcoming conferences: FBR Inaugural Healthcare Conference, Boston, MA, September 3 rd (no presentation or webcast) Morgan Stanley Healthcare Conference 2014, New York, September 8 th , at 11:40 a.m. ET A live webcast of Infinity's presentation at the Morgan Stanley Conference will be accessible on the “investors/media” section of the company's website, www.infi.com , and will be available for 30 days following each event.
Sign-up for Infinity to Participate in Two Conferences in September investment picks
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the Deutsche Bank Securities 2014 BioFEST Conference on December 1, 2014 at 2:15 p.m. ET in Boston.
Sign-up for Infinity to Present at the Deutsche Bank Securities 2014 BioFEST Conference investment picks
2014/9/29
Insurance firms are making a significant move toward private market assets to diversify against the risks that have traditionally underpinned their businesses, a new BlackRock-commissioned study of insurers with over $6.2 trillion of assets has found.
Sign-up for Inflation Risks and Thirst for Yield Drive Insurers to Private Markets investment picks
Infoblox Inc. (NYSE:BLOX) today announced the promotion of Thorsten Freitag to Executive Vice President, Worldwide Field Operations, effective October 1, 2014.
Sign-up for Infoblox Appoints Thorsten Freitag as Executive Vice President of Worldwide Field Operations investment picks
Infoblox Inc. (NYSE:BLOX), the network control company, today announced enhancements to its Infoblox NetMRI product that enable it to discover, track, and manage virtual routing and forwarding (VRF) of network traffic — a technology essential to next-generation data centers and multi-tenant computing.
Sign-up for Infoblox Delivers Network Automation for Next-Generation Data Centers with the First Solution That Discovers and Manages Virtually Routed Networks in Multivendor Environments investment picks
Infoblox Inc. (NYSE:BLOX), the network control company, today announced the Infoblox OpenStack Adapter, delivering the first open-source connector for bringing enterprise-grade network control to the OpenStack platform.
Sign-up for Infoblox Introduces the First Open-Source Adapter That Brings Enterprise-Grade Network Control to OpenStack investment picks
Infoblox (NYSE:BLOX), the automated network control company, today reported its financial results for its fourth fiscal quarter ended July 31, 2014.
Sign-up for Infoblox Reports Fourth Quarter of Fiscal 2014 Results investment picks
SANTA CLARA, Calif., Nov.
Sign-up for Infoblox to Announce Fiscal First Quarter 2015 Results investment picks
Redwood City, Calif., Oct.
Sign-up for Informatica Cloud Chosen by NI for Complete Customer Views investment picks
Las Vegas, Nevada - re:Invent 2014, Nov.
Sign-up for Informatica Goes All-In on AWS to Help Enterprises Move to the Cloud investment picks
Las Vegas, Nevada - re:Invent 2014, Nov.
Sign-up for INFORMATICA GOES ALL-IN ON AWS TO HELP ENTERPRISES MOVE TO THE CLOUD (update) investment picks
http://media.marketwire.com/attachments/201409/79444_bluewold.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1145096&ProfileId=051205&sourceType=1 NEW YORK, NY and REDWOOD CITY, CA --
Sign-up for Informatica Joins Bluewolf's Global Analytics Practice to Power Business Intelligence investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Infinera to Host Light on a Chip: The Future of Photonic Integration Webinar on December 10, 2014 to Informatica Joins Bluewolf's Global Analytics Practice to Power Business Intelligence
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent